Dual inhibition of LOX and CLOCK-OLFML3 axis extends the survival of PTEN-deficient GBM-bearing mice and leads to disease eradication in majority of tumor-bearing mice when combined with anti-PD1 therapy. This evidence concerns the gene LOX and neoplasm.